NUCLEIC ACID APTAMER
|Posted date||Jan 28, 2021|
|International application number||2020JP020119|
|International publication number||WO 2020235635|
|Date of international filing||May 21, 2020|
|Date of international publication||Nov 26, 2020|
|Title||NUCLEIC ACID APTAMER|
|Abstract||A nucleic acid aptamer that is capable of forming a guanine quadruplex structure in the presence of a cation and has a cell membrane permeability, wherein the nucleic acid aptamer comprises first, second, third and fourth regions forming the guanine quadruplex structure and connection regions A, B and C positioned respectively between the first and second regions, between the second and third regions and between the third and fourth regions; the first region has the base sequence represented by SEQ ID NO: 1; the second, third and fourth regions each have the base sequence represented by SEQ ID NO: 2; and at least one region selected from the group consisting of the connection regions A, B and C is capable of specifically binding to a target molecule in the presence of a cation.|
|Outline of related art and contending technology||
In recent years, antibody pharmaceuticals have become highly aggressive as therapeutic agents for cancer, but in addition to the high drug value, the type of disease-associated protein that can be handled is a plateau, and the limitation of antibody pharmaceuticals has also been seen. Therefore, development of post-antibody pharmaceuticals having a maternal structure different from that of antibodies is strongly desired. DNA / RNA aptamers formed from single-stranded DNA or RNA and having high binding capacity and selectivity with respect to biomolecules containing proteins are inexpensive to synthesize and have low antigenicity. therefore, attention is focused on as target recognition molecules instead of antibodies. Previously approved aptamer drugs include pegaptanib (trade name "Macugen", U.S. approved 2004, and Japanese approved 2008), which are drugs for treating age-related macular degeneration (, for example, see Patent Document 1.
However, antibody pharmaceuticals and nucleic acid aptamer pharmaceuticals approved thus far cannot permeate through the cell membrane, and thus the target is limited to extracellular. Therefore, it is desirable to develop a molecular targeting drug that can permeate through the cell membrane while maintaining the high molecular recognition ability and binding ability of antibodies and nucleic acid aptamers.
Furthermore, as a method for introducing a protein such as an antibody into a cell, a method using uptake into a cell by fusion or mixing with a transmembrane peptide and a method for introducing into a cell by liposome or the like have been known, but it has not been possible to put it into practical use because it is difficult to aggregate a target molecule and introduce only a specific molecule into a cell.
|Scope of claims||
|IPC(International Patent Classification)|
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL ST SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
※ Please contact us by E-mail or facsimile if you have any interests on this patent.
Contact Information for " NUCLEIC ACID APTAMER "
- Niigata University (In Japanese)研究支援部産学連携課
- URL: https://www.niigata-u.ac.jp/
- Address: 8050,Ikarashi 2no-cho,Nishi-Ku,Niigata,Japan , 950-2181
- Phone: 81-25-262-7554
- Fax: 81-25-262-7513